Consolidation UNITED STATES FORM 10-K Delaware 81-0980861 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) SIGNATURES PART I Item 1. Business Item 1A. Risk Factors Item 1B. Unresolved Staff Comments Item 2. Properties Item 3. Legal Proceedings Item 4. Mine Safety Disclosures Table of Contents The Company is an accelerated public company filer. Therefore, required effective dates for adopting new or revised accounting standards are generally earlier than whe ...

Bioventus Inc. (NASDAQ:BVS) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Dave Crawford - VP of IR Ken Reali - CEO Mark Singleton - SVP and CFO Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group Caitlin Cronin - Canaccord Genuity Drew Ranieri - Morgan Stanley Philip Coover - Goldman Sachs Rohin Patel - JPMorgan Operator Good day, and welcome to Bioventus Inc. Third Quarter 2022 Earnings Conference Call. All participants will be in a listen-only ...

Bioventus Inc. (NASDAQ:BVS) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Dave Crawford - VP of IR Ken Reali - CEO Mark Singleton - SVP and CFO Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Robbie Marcus - JPMorgan Drew Ranieri - Morgan Stanley Phil Coover - Goldman Sachs Operator Good morning, and welcome to the Bioventus Incorporated Second Quarter 2022 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions]. ...

August 11, 2022 Q1 2021 Results Innovations For Active Healing Second Quarter 2022 Financial Results Agenda and Speakers Ken Reali Chief Executive Officer Q2 2022 Review Progress on 2022 Priorities Mark Singleton Senior Vice-President and Chief Financial Officer Q2 2022 Results CartiHeal Financing 2022 Guidance Forward Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of ...

Bioventus Inc. (NASDAQ:BVS) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Dave Crawford - Vice President of Investor Relations Ken Reali - Chief Executive Officer Mark Singleton - Senior Vice President and Chief Financial Office Conference Call Participants Alex Nowak - Craig Hallum Operator Good day and thank you for standing by. Welcome to Bioventus First Quarter 2022 Earnings Conference Call. [Operator Instructions] Please be advised that todayÂ's conference is being recor ...

May 10, 2022 Q1 2021 Results Innovations For Active Healing First Quarter 2022 Financial Results Agenda and Speakers Ken Reali Chief Executive Officer Q1 2022 Review Progress on 2022 Priorities Mark Singleton Senior Vice-President and Chief Financial Officer Q1 2022 Results 2022 Guidance Forward Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Se ...

Q1 2021 Results Innovations For Active Healing Fourth Quarter 2021 Financial Results March 10, 2022 Agenda and Speakers Ken Reali Chief Executive Officer Q4 2021 Review 2022 Priorities Dave Crawford Vice President Investor Relations and Treasurer Q4 2021 Results 2022 Guidance Forward Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of ...

Bioventus Inc. (NASDAQ:BVS) Q4 2021 Earnings Conference Call March 10, 2022 8:30 AM ET Company Participants Ken Reali – Chief Executive Officer Dave Crawford – Vice President of Investor Relations Conference Call Participants Kyle Rose – Canaccord Genuity Drew Ranieri – Morgan Stanley Robbie Marcus – JP Morgan Phil Coover – Goldman Sachs Operator Thank you for standing by and welcome to the Bioventus Incorporated, Fourth Quarter 2021 earnings conference call. At this time, all participants are in a listen- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 10-K ________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission File Number: 001-37844 BIOVENTUS INC. (Exact Name of Registrant as Spec ...

Bioventus Inc. (NASDAQ:BVS) Q3 2021 Earnings Conference Call November 9, 2021 8:30 AM ET Company Participants Dave Crawford - Vice President of Investor Relations Ken Reali - Co-Founder & Chief Executive Officer Greg Anglum - Chief Financial Officer Conference Call Participants Kyle Rose - Canaccord Genuity Drew Ranieri - Morgan Stanley Operator Good day and thank you for standing by. Welcome to the Bioventus Inc. Third Quarter of Fiscal Year 2021 Earnings Conference Call. At this time, all participants are ...